ArticleTargeted oncology2025

Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.

Jose De La Cerda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.